In this photo illustration the American multinational pharmaceutical corporation Pfizer logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.
Budrul Chukrut | SOPA Images | Getty Images
Pfizer shares jumped by nearly 7% in premarket trading Wednesday after it released positive results from its closely watched early-stage human trial on a coronavirus vaccine.
The trial evaluated 45 people. Each participant received either a 10, 30 or 100 microgram dose of the vaccine or a placebo.
The company coronavirus vaccine produced neutralizing antibodies in participants after 28 days, according to the preliminary data.
The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech. The company’s experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response for the virus.
This is a developing story. Please check back for updates.
